Oncology Views & Analysis | pharmaphorum

Saturday 7 February 2026

Views & Analysis

Views & Analysis

Oncology-Round-up-16x9-3

Oncology round-up: CAR-T conference raises hopes for solid t...

Kisaco Research’s CAR-T Congress EU could not have come at a better time – the day after it finished NICE announced it had granted funding for a new use for Novartis’ cancer cell therapy Ky

Views & Analysis

2018-Review-Oncology-16x9

2018 in review: Merck & Co sets new standards in oncology, C...

Oncology drugs are developing at a fast pace, but 2018 was the year when immune-oncology set new standards for several of the most common forms of the disease.

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

Views & Analysis

Feautre-16x9

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers.

Views & Analysis

eye-on-innovation-16x9-P-Mahaffy

Dreaming big with small molecules

Clovis Oncology has gone from a small biotech to a pharma company with a cutting-edge cancer drug approved and on the market in less than a decade.

Oncology

approximate the DNA molecule on a blue background

Has the NHS joined the biosimilars revolution?

Biosimilars have cut the price of biologic drugs by up to 80% on the NHS, according to Paul Clark, Napp’s director of biosimilars.